<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Osteoporosis: prevention and treatment.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;University of Michigan Health System. Osteoporosis:  prevention and treatment. Ann Arbor (MI): University of Michigan Health System; 2011 Dec. 16 p.  [13 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: University of Michigan Health System. Osteoporosis: prevention and treatment. Ann Arbor (MI): University of Michigan Health System; 2010 Jul. 15 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Bone mineral density studies  (88.98); Fracture, cause unspecified  (E887); Osteoporosis, unspecified  (733.00)"/><FieldValue Value="MSH: Absorptiometry, Photon ; Accident Prevention ; Accidental Falls ; Alendronate ; Antibodies, Monoclonal ; Biological Markers ; Bone Density ; Bone Density Conservation Agents ; Bone Resorption ; Calcitonin ; Calcitriol ; Calcium ; Calcium, Dietary ; Diphosphonates ; Drug Therapy, Combination ; Estrogen Replacement Therapy ; Estrogens ; Etidronic Acid ; Exercise ; Exercise Therapy ; Fractures, Bone ; Glucocorticoids ; Hip Fractures ; Hormone Replacement Therapy ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Imidazoles ; Isoflavones ; Motor Activity ; Organ Transplantation ; Osteoporosis ; Osteoporosis, Postmenopausal ; Parathyroid Hormone ; Phytoestrogens ; Postmenopause ; Progestins ; Referral and Consultation ; Risk Assessment ; Risk Factors ; Selective Estrogen Receptor Modulators ; Smoking Cessation ; Spinal Fractures ; Tamoxifen ; Testosterone ; Ultrasonography ; Vitamin D "/><FieldValue Value="MTH: Accidental Falls ; Biological Markers ; Bone Density ; Bone Mineral Density Test ; Calcitonin ; Calcitriol ; Calcium ; Calcium, Dietary ; Cessation of smoking ; Combination Drug Therapy ; denosumab ; Diphosphonates ; Estrogen Replacement Therapy ; Estrogens ; Exercise ; Fall prevention ; follow-up ; Fracture ; Glucocorticoids ; Hip Fractures ; Hormone replacement therapy ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Ibandronate ; Imidazoles ; Monoclonal Antibodies ; Organ Transplantation ; Osteoporosis ; Osteoporosis, Postmenopausal ; Parathyroid Hormone ; Physical activity ; Physical therapy exercises ; Progestins ; Risedronate ; Risk Assessment ; risk factors ; Selective Estrogen Receptor Modulators ; Spinal Fractures ; Tamoxifen ; Testosterone ; Thiazide Diuretics ; Ultrasonography ; Vitamin D ; zoledronic acid "/><FieldValue Value="PDQ: biological markers ; calcitonin ; calcitriol ; denosumab ; ibandronate ; isoflavones ; organ transplantation ; osteoporosis ; parathyroid hormone ; risedronate ; therapeutic testosterone ; ultrasonography "/><FieldValue Value="SNOMEDCT_US: Accident prevention  (134185000); Accidental fall  (217082002); Alendronate  (96290008); Assessment using World Health Organization fracture risk assessment tool for osteoporotic fracture probability  (445984005); Bone resorption  (22200009); Calcitonin  (63730009); Calcitriol preparation  (259333003); Calcitriol preparation  (68206008); Calcium  (5540006); Denosumab  (446321003); Denosumab  (446457007); Diphosphonate  (372907000); Diphosphonate  (96281001); Education about alcohol consumption  (281078001); Estrogen  (41598000); Estrogen  (61946003); Estrogen-progestin preparation  (84772008); Etidronic acid  (420702005); Etidronic acid  (96284009); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Fall prevention  (386296001); Fracture  (125605004); Fracture  (72704001); Fracture of vertebral column  (50448004); Glucocorticoid  (116596006); Glucocorticoid  (35150008); Glucocorticoid  (419933005); Hip protector  (705331006); HMG-CoA reductase inhibitor  (372912004); HMG-CoA reductase inhibitor  (96302009); Hormone replacement therapy  (266717002); Ibandronate  (96287002); Monoclonal antibody  (49616005); Osteoporosis  (64859006); Osteoporosis - falls prevention  (391027005); Osteoporotic fracture probability score using World Health Organization fracture risk assessment tool  (446965002); Parathyroid hormone  (27518004); Parathyroid hormone  (373752003); Parathyroid hormone  (4076007); Physical activity  (48761009); Physical activity  (68130003); Postmenopausal osteoporosis  (102447009); Postmenopausal osteoporosis  (32369003); Progestogen  (116614001); Progestogen  (20249007); Risedronate  (387582001); Risk assessment  (225338004); Risk factor  (80943009); Selective estrogen receptor modulator  (109030001); Selective estrogen receptor modulator  (415515000); Tamoxifen  (373345002); Tamoxifen  (75959001); Testosterone  (109033004); Testosterone  (43688007); Therapeutic exercise  (226029000); Therapeutic exercise  (229065009); Therapeutic exercise  (51998003); Thiazide diuretic  (372747003); Thiazide diuretic  (45518007); Ultrasonography  (16310003); Ultrasonography  (278292003); Ultrasonography  (359659005); Vitamin D  (11563006); Vitamin D  (30178006); Zoledronic acid  (134600006); Zoledronic acid  (395926009)"/><FieldValue Value="SPN: SYSTEM, IMAGING, PULSED DOPPLER, ULTRASONIC "/><FieldValue Value="UMD: Densitometers, Bone, X-Ray, Dual-Energy Absorptiometry  (17-747); Scanning Systems, Ultrasonic  (14-278); Shields, Mechanical, Hip  (18-012)"/></Field></Section><Section SecID="394" OrdBy="200" Name="Regulatory Alert"><Field FieldID="154" OrdBy="205" ID="395" Name="FDA Warning/Regulatory Alert" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse&lt;/strong&gt;: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm436280.htm&quot; title=&quot;FDA Web site&quot; target=&quot;_blank&quot;&gt;March 3, 2015 &amp;ndash; Testosterone Products&lt;/a&gt;: The U.S. Food and Drug Administration (FDA) is requiring that the manufacturers of all approved prescription testosterone products change their labeling to clarify the approved uses of these medications. FDA is also requiring these manufacturers to add information to the labeling about a possible increased risk of heart attacks and strokes in patients taking testosterone. FDA cautions that prescription testosterone products are approved only for men who have low testosterone levels caused by certain medical conditions. The benefit and safety of these medications have not been established for the treatment of low testosterone levels due to aging, even if a man's symptoms seem related to low testosterone.&lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Osteoporosis in postmenopausal women &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Secondary osteoporosis related to long-term glucocorticoid use, organ transplant, or other medical conditions &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Endocrinology" /><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Preventive Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To decrease osteoporotic fractures and their associated morbidity and mortality&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Postmenopausal women and persons at risk for secondary osteoporosis related to long-term glucocorticoid use, organ transplant, or other medical conditions&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Prevention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Weight bearing exercise &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adequate dietary calcium and vitamin D &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Regular physical activity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Avoiding heavy alcohol consumption and smoking &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Minimizing exposure to glucocorticoid therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Preventive use of bisphosphonates during glucocorticoid therapy &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Risk Assessment/Diagnosis/Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assessment of risk factors (e.g., age, smoking status, body weight, frailty, history of fracture, chronic glucocorticoid use, organ transplant status, other associated medical conditions and medications, and risk for falling) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dual emission x-ray absorptiometry (DXA) measurement of bone mineral density (BMD) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of FRAX (fraction risk assessment tool) to assess for need for DXA or treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quantitative calcaneal ultrasound devices (considered but not recommended) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Measurement of biochemical markers of bone resorption (considered but not recommended) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evaluation and referral for secondary causes of osteoporosis &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment/Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Non-pharmacologic therapies&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Weight bearing exercises &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Fall prevention measures &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Anatomically designed hip protectors &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pharmacologic therapies&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Calcium and vitamin D &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Bisphosphonates (such as alendronate, risedronate, zoledronic acid, and ibandronate) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Denosumab &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Parathyroid hormone (teriparatide) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Selective estrogen receptor modulators (SERMs) (e.g., raloxifene) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Estrogen and progestin (and combinations) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Calcitonin nasal spray &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Other pharmacologic therapies (considered but not necessarily recommended at this time)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Combination therapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Calcitriol &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Tamoxifen &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Testosterone replacement or supplement in men &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Thiazide diuretics (e.g., hydrochlorothiazide) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Phytoestrogens, including isoflavones &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Follow-up: repeat DXA measurement &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Risk for osteoporosis and osteoporotic fractures &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of osteoporosis and osteoporotic fractures &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;T-score &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Predictive value of diagnostic tests (DXA) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mortality related to osteoporotic hip fractures &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Morbidity (chronic pain, disability, deformity, depression) related to osteoporotic fractures &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pain relief &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Medication side effects &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of falls &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The literature search for this update began with the results of the search performed for the 2002 version of this guideline. That search began with the results of a search performed by the National Osteoporosis Foundation (Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis), published in 1998 and including literature through 1996. Medline was then searched for literature from 1996 through 1999. Details of that search (similar to the update search explained below) were described in the 2000 guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The search for the 2010 update of this guideline was performed on literature from 2000 through April 2007. The search was conducted prospectively using the major key words of: osteoporosis (including osteoporosis, postmenopausal); osteopenia; English language; and guidelines or controlled trials. Specific searches were performed for special risk categories (steroids, transplant, men/males/ non-Caucasian women/African-American women). For postmenopausal osteoporosis, specific searches were performed for risk factors (general risk factors, progestins, aromatase inhibitors, parathyroid), diagnostic testing (bone density scan/DXA, metabolic bone markers, bone quality, ultrasound), pharmacologic therapies (calcium, Vitamin D/calcitriol, bisphosphonates, raloxifene, calcitonin, hormone replacement therapy, teriparatide, tamoxifen/SERMS, testosterone/androgens, thiazide diuretics, HMG-coA-reductase inhibitors, phytoestrogens, strontium), non-pharmacologic strategies (exercise, fall prevention), alternative and complementary therapies (phytoestrogens, isoflavanoids), and monitoring (DXA frequency). The detailed search strategy is available upon request.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The search was conducted in components each keyed to a specific causal link in a formal problem structure (available upon request). The search was supplemented with very recent (through June 2009) clinical trials known to expert members of the panel. Negative trials were specifically sought. The search was a single cycle.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The review of literature was assisted by the publication in December 2007 of a systematic review of treatments: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. The Agency for Healthcare Research published this review, which examined literature from 1966 through December 2006.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The 2011 interim revision of the guideline was based on literature reviews performed for recently published national guidelines and very recently recent (through July 2011) clinical trials known to expert members of the panel. The topic of denosumab was added.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Randomized controlled trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled trials, no randomization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Observational trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Opinion of expert panel &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Conclusions were based on prospective randomized controlled trials (RCTs), if available, to the exclusion of other data. If RCTs were not available, observational studies were admitted to consideration. If no such data were available for a given link in the problem formulation, expert opinion was uses to estimate effect size. The &quot;strength of recommendation&quot; for key aspects of care was determined by expert opinion.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Generally should be performed &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;May be reasonable to perform &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Generally should not be performed&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Drafts of this guideline were reviewed in clinical conferences and by distribution within departments and divisions of the University of Michigan Medical School to which the content is most relevant: Family Medicine, General Medicine, Geriatric Medicine, Metabolism and Endocrinology, and Obstetrics and Gynecology (Women's Health). The Executive Committee for Clinical Affairs of the University of Michigan Hospitals and Health Centers endorsed the final version.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;em&gt;Note from the University of Michigan Health System (UMHS) and the National Guideline Clearinghouse (NGC)&lt;/em&gt;&lt;/strong&gt;: The following guidance was current as of December 2011. Because UMHS occasionally releases minor revisions to its guidance based on new information, users may wish to consult the &lt;a href=&quot;http://www.med.umich.edu/1info/fhp/practiceguides/osteoporosis.html&quot; title=&quot;UMHS Web site&quot;&gt;original guideline document&lt;/a&gt; for the most current version.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Note from NGC&lt;/strong&gt;: The following key points summarize the content of the guideline. Refer to the full text of the original guideline document for detailed information on diagnosis, risk assessment, screening, prevention, treatment, and medications.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The strength of recommendation (I-III) and levels of evidence (A-D) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Definitions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Bone mineral density&lt;/em&gt; [BMD] correlates with skeletal strength and fracture risk.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Dual-energy X-ray absorptiometry&lt;/em&gt; [DXA] measures BMD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A DXA &lt;em&gt;T-score&lt;/em&gt; is the number of standard deviations from mean BMD in young adults.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Osteoporosis&lt;/em&gt; is defined as a DXA T-score &amp;le;-2.5, &lt;em&gt;osteopenia&lt;/em&gt; as &amp;gt;-2.5 but &amp;lt;-1.0 (see Table 1 in the original guideline document).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;General Clinical Relevance&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Fractures related to osteoporosis are common and have high morbidity &lt;em&gt;[C]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Glucocorticoids can cause significant bone loss, particularly during the first 6-12 months of use &lt;em&gt;[B]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Prevention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Across life span: appropriate calcium and vitamin D (see Table 9 in the original guideline document) and weight bearing exercise &lt;em&gt;[ID]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Risk Assessment and Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Assess all adults, men and women, for clinical risk factors for osteoporotic fracture (see Tables 2 and 3 in the original guideline document) &lt;em&gt;[IC]&lt;/em&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Postmenopausal woman with one or more of the following:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Age &amp;ge;65 years &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Current smoking &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Low body weight (BMI &amp;lt;20) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Frailty (e.g., unable to rise from chair unassisted) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Personal history of fracture without substantial trauma &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Hip, wrist, or spine fracture without substantial trauma in 1st degree relative &amp;ge;50 &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chronic glucocorticoid use (prednisone &amp;ge;5 mg daily, or equivalent, for &amp;ge;3 months) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Organ transplant or pending transplant &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk for falling (see Table 4 in the original guideline document) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Other associated medical conditions (see Table 2 in the original guideline document) and medications (see Table 3 in the original guideline document) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Order DXA &lt;em&gt;[IA]&lt;/em&gt; based on clinical risk factors and potential impact of results on management (see Table 5 in the original guideline document).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For women under 65, FRAX (World Health Organization Fracture Risk Assessment Tool; &lt;a href=&quot;http://www.shef.ac.uk/FRAX/&quot; title=&quot;FRAX Tool Web site&quot;&gt;http://www.shef.ac.uk/FRAX/&lt;/a&gt;) can be used to assess need for screening DXA.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;DXA is indicated for women with 10-year total fracture risk of 9.3% (equivalent to that of a healthy 65 year-old woman). In this setting, FRAX can be used without entering BMD data.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Evaluate appropriately and refer, when indicated, for secondary causes of osteoporosis (see Table 6 in the original guideline document) &lt;em&gt;[IID]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For treatment-naive women, FRAX (&lt;a href=&quot;http://www.shef.ac.uk/FRAX/&quot;&gt;http://www.shef.ac.uk/FRAX/&lt;/a&gt;) can be used to assess need for treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Begin medical therapy for 10-year fracture risks of &amp;gt;3% at hip or &amp;gt;20% total fracture risk. For other patients, based on T-score and clinical risk factors (see Tables 2, 3&amp;nbsp;and 5 in the original guideline document), begin medical therapy for:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Prior osteoporosis-related fracture, or T-score &amp;lt;-2.5 &lt;em&gt;[IA]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;T-score &amp;le;-1 and (a) glucocorticoid use or (b) pending or post-transplant, especially if on steroids or (c) postmenopausal woman at high risk &lt;em&gt;[IA])&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;T-score between -2 and -2.5 in postmenopausal woman &lt;em&gt;[IA]&lt;/em&gt; and patients with appropriate risk factors. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;When starting glucocorticoids, consider medical therapy to prevent or treat osteoporosis &lt;em&gt;[IIA]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Base medical therapy (see Tables 7 and 9 in the original guideline document) on clinical benefits and potential risks &lt;em&gt;[I]&lt;/em&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;In post-menopausal women with osteoporosis:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Alendronate, denosumab, estrogen, risedronate, and zoledronic acid reduce hip and vertebral fracture risk &lt;em&gt;[A]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Ibandronate, raloxifene, teriparatide, and calcitonin reduce vertebral fracture risk &lt;em&gt;[IA]&lt;/em&gt; &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In men with osteoporosis, alendronate reduces vertebral fracture risk &lt;em&gt;[A]&lt;/em&gt; (probably class effect &lt;em&gt;[D])&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If on a glucocorticoid, use bisphosphonates (oral or intravenous [IV]) &lt;em&gt;[A]&lt;/em&gt;. For alternative treatments, consider teriparatide or denosumab &lt;em&gt;[A]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Follow-up&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Repeat DXA based on patient's situation (see Tables 5 and 8 in the original guideline document) &lt;em&gt;[IC-D]&lt;/em&gt;. Consider not repeating DXA on patients with moderate bone loss who are fracture-free on medical therapy &lt;em&gt;[IIC]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For most persons, &amp;ge;2 years between DXAs provides the most meaningful information &lt;em&gt;[B]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Early in glucocorticoid use and/or after transplantation consider repeating DXA in 6-12 months &lt;em&gt;[IB]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Randomized controlled trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled trials, no randomization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Observational trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Opinion of expert panel &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Generally should be performed &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;May be reasonable to perform &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Generally should not be performed &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Conclusions were based on prospective randomized controlled trials (RCTs), if available, to the exclusion of other data. If RCTs were not available, observational studies were admitted to consideration. If no such data were available for a given link in the problem formulation, expert opinion was uses to estimate effect size.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Improved identification of patients at high risk for osteoporosis and osteoporotic fractures &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Decreased incidence of osteoporotic fractures and associated morbidity and mortality &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Non-drug Therapies&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Anatomically designed hip protectors&lt;/em&gt;. Hip protectors are often difficult to put on, and uncomfortable to wear; therefore, compliance may play a role in reducing their potential effectiveness.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Drug Therapies&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Calcium&lt;/em&gt;. Constipation is more common with calcium carbonate. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Vitamin D&lt;/em&gt;. Vitamin D is fat-soluble, and thus toxicity can result from excess dosing. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Bisphosphonates&lt;/em&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Oral bisphosphonate trials have reported esophageal complications ranging from heartburn and acid reflux to esophageal ulceration and perforation, which are quite rare. The FDA is currently investigating a possible connection between esophageal cancer and oral bisphosphonates. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Effects on fetal development are not known. Prolonged presence in bone of treated patients: discuss potential fetal risks if considering for women of child-bearing age. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Osteonecrosis of the jaw (ONJ) has emerged as a more serious complication of high dose bisphosphonate therapy. Risk of ONJ is less than 1 in 100,000 for oral bisphosphonates. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Bisphosphonate use has been associated with musculoskeletal pain, and this side effect has been included in the prescribing information for all drugs in this class. However, in January 2008, the U.S. Food and Drug Administration (FDA) highlighted this risk, reminding clinicians to consider bisphosphonates when evaluating patients with musculoskeletal pain. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Atypical femoral shaft fractures may also be associated with bisphosphonate use, and is being investigated by the FDA. These fractures tend to occur without trauma, and may be preceded by the sudden onset of thigh pain. The estimated risk of this complication is 1:10.000. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;&lt;em&gt;Zoledronic acid&lt;/em&gt; has been associated with a small increase in atrial fibrillation. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Denosumab&lt;/em&gt; is associated with an increased risk of cellulitis, although the risk is low (&amp;lt;0.5%). Other infections may be more common in patients on denosumab. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Teriparatide&lt;/em&gt;. Teriparatide was associated with an increased incidence of osteosarcoma in rats given high doses over an extended period. Given this concern, it should not be used in patients with a history of bony malignancy, or those at risk. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Raloxifene&lt;/em&gt;. An increased risk of deep venous thrombosis and pulmonary embolism approximately the same as estrogen therapy, as well as hot flashes have been associated with raloxifene. Raloxifene is not recommended for use in premenopausal women. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Estrogen&lt;/em&gt;. Preparations and formulations identified as 'bioidentical hormones' do not have evidence demonstrating benefit in fracture reduction, or even safety, when compared to FDA-approved sources of estrogen. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Calcitonin nasal spray&lt;/em&gt;. Rhinitis has been observed in 5% excess compared with placebo. Caution is urged with calcitonin nasal spray in renal failure. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Reflux without esophagitis is a relative but not an absolute contraindication of bisphosphonates. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bisphosphonates should be avoided if creatinine clearance is &amp;lt;30 to 35. Bisphosphonates should not be used in women who are, or plan to become pregnant.&lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;These guidelines should not be construed as including all proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Foreign Language Translations" /><FieldValue Value="Patient Resources" /><FieldValue Value="Staff Training/Competency Material" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;University of Michigan Health System. Osteoporosis:  prevention and treatment. Ann Arbor (MI): University of Michigan Health System; 2011 Dec. 16 p.  [13 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2002 Mar (revised 2011 Dec)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="University of Michigan Health System - Academic Institution" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;University of Michigan Health System&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Osteoporosis Guideline Team&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Team Leader&lt;/em&gt;: Robert W. Lash, MD, Endocrinology&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Team Members&lt;/em&gt;: R. Van Harrison, PhD, Medical Education; Jane T. McCort, MD, General Medicine; Jane M. Nicholson, MD, Obstetrics/Gynecology; Lourdes Velez, MD, Family Medicine&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Guidelines Oversight Team&lt;/em&gt;: Connie J Standiford, MD; Grant Greenberg, MD, MA, MHSA; R Van Harrison, PhD&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The University of Michigan Health System endorses the Guidelines of the Association of American Medical Colleges and the Standards of the Accreditation Council for Continuing Medical Education that the individuals who made to provide readers with information that might be of potential importance to their evaluation of the information.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table: Conflicts of Interest&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Team Member&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Relationship&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Company&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Van Harrison, PhD &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;(None)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Robert Lash, MD&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;(None)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Jane McCort, MD&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;(None)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Jane Nicholson, MD&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;(None)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lourdes Velez, MD&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;(None)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: University of Michigan Health System. Osteoporosis: prevention and treatment. Ann Arbor (MI): University of Michigan Health System; 2010 Jul. 15 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1info/fhp/practiceguides/osteoporosis.html&quot; title=&quot;UMHS Web site&quot;&gt;University of Michigan Health System Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Continuing Medical Education (CME) information is available from the &lt;a href=&quot;http://cme.med.umich.edu/iCME/osteo10/default.asp&quot; title=&quot;UMHS Web site&quot;&gt;University of Michigan Health System Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Osteoporosis in women. Patient education handout. Ann Arbor (MI): University of Michigan Health System; 2009 Jul. Various p. Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1libr/guides/osteo.htm&quot; title=&quot;UMHS Web site&quot;&gt;University of Michigan Health System (UMHS) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Calcium and vitamin D. Patient education handout. Ann Arbor (MI): University of Michigan Health System; 2010 Aug. Various p. Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1libr/guides/calcium.htm&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. Also available in Spanish from the &lt;a href=&quot;http://www.med.umich.edu/1libr/guides/calciums.htm&quot; title=&quot;UMHS Web site&quot;&gt;UMHS Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on March 19, 2003. The information was verified by the guideline developer on April 23, 2003. This NGC summary was updated by ECRI on September 22, 2005. The updated information was verified by the guideline developer on November 1, 2005. This NGC summary was updated by ECRI Institute on October 14, 2010. This summary was updated by ECRI Institute on December 10, 2010 following the U.S. Food and Drug Administration (FDA) advisory on Bisphosphonates. This summary was updated by ECRI Institute on October 12, 2011 following the U.S. Food and Drug Administration (FDA) advisory on Reclast (zoledronic acid). This NGC summary was updated by ECRI Institute on March 23, 2012. This summary was updated by ECRI Institute on April 3, 2015 following the U.S. Food and Drug Administration advisory on Testosterone Products.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is copyrighted by the University of Michigan Health System (UMHS).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
